Merck pays $110m for OncoEthix and ex-Mitsubishi oncology candidate
This article was originally published in Scrip
Executive Summary
Merck & Co has acquired OncoEthix, a private Swiss oncology-focused biotechnology company, for $110m upfront and up to $265m in clinical and regulatory milestones. Merck gains an oral BET (bromodomain and extra-terminal protein) inhibitor, OTX015, which is currently in Phase I studies for the treatment of hematological malignancies and advanced solid tumors.